tbuckley/cabot-search huggingface dataset:
Changes in ventricular 1,2-diacylglycerol content in rats following monocrotaline treatment
Authors: K. Okumura, J. Kondo, K. Shimizu, M. Yoshino, Y. Toki, H. Hashimoto, T. Ito
Journal: Cardiovascular Research (1992)

Journal Article Changes in ventricular 1,2-diacylglycerol content in rats following monocrotaline treatment Get access Kenji Okumura, Kenji Okumura Second Department of Internal Medicine, Nagoya University School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466, Japan: K Okumura, J Kondo, K Shimizu, M Yoshino, Y Toki, H Hashimoto, T Ito. Correspondence to Dr Okumura. Search for other works by this author on: Oxford Academic PubMed Google Scholar Junichiro Kondo, Junichiro Kondo Second Department of Internal Medicine, Nagoya University School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466, Japan: K Okumura, J Kondo, K Shimizu, M Yoshino, Y Toki, H Hashimoto, T Ito. Search for other works by this author on: Oxford Academic PubMed Google Scholar Kiyokazu Shimizu, Kiyokazu Shimizu Second Department of Internal Medicine, Nagoya University School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466, Japan: K Okumura, J Kondo, K Shimizu, M Yoshino, Y Toki, H Hashimoto, T Ito. Search for other works by this author on: Oxford Academic PubMed Google Scholar Mitsuhiko Yoshino, Mitsuhiko Yoshino Second Department of Internal Medicine, Nagoya University School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466, Japan: K Okumura, J Kondo, K Shimizu, M Yoshino, Y Toki, H Hashimoto, T Ito. Search for other works by this author on: Oxford Academic PubMed Google Scholar Yukio Toki, Yukio Toki Second Department of Internal Medicine, Nagoya University School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466, Japan: K Okumura, J Kondo, K Shimizu, M Yoshino, Y Toki, H Hashimoto, T Ito. Search for other works by this author on: Oxford Academic PubMed Google Scholar Hidekazu Hashimoto, Hidekazu Hashimoto Second Department of Internal Medicine, Nagoya University School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466, Japan: K Okumura, J Kondo, K Shimizu, M Yoshino, Y Toki, H Hashimoto, T Ito. Search for other works by this author on: Oxford Academic PubMed Google Scholar Takayuki Ito Takayuki Ito Second Department of Internal Medicine, Nagoya University School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466, Japan: K Okumura, J Kondo, K Shimizu, M Yoshino, Y Toki, H Hashimoto, T Ito. Search for other works by this author on: Oxford Academic PubMed Google Scholar Cardiovascular Research, Volume 26, Issue 6, June 1992, Pages 626–630, https://doi.org/10.1093/cvr/26.6.626 Published: 01 June 1992 Article history Received: 24 June 1991 Accepted: 20 January 1992 Published: 01 June 1992
NHS chief is forbidden from lobbying health department for two years after moving to private sector
Authors: G. Iacobucci
Journal: BMJ (2012)

Jim Easton, national director of improvement and efficiency at the Department of Health, will become the new managing director of the healthcare division of the private company Care UK from January 2013. 

His move to the private healthcare provider has sparked concern about civil servants who transfer to the private sector benefiting from government policies. Just last week Labour urged the government to re-examine the rules governing the transfer of senior civil servants.1

Easton led the Department of Health’s quality, innovation, productivity, and …
Quinolone-Based Antibacterial Chemoprophylaxis in Neutropenic Patients: Effect of Augmented Gram-Positive Activity on Infectious Morbidity
Authors: Eric J. Bow
Journal: Annals of Internal Medicine (1996)

Objective: To determine whether augmented quinolone-based antibacterial prophylaxis in neutropenic patients with cancer reduces infections caused by gram-positive cocci and preserves the protective effect against aerobic gram-negative bacilli. Design: Open, randomized, controlled, multicenter clinical trial. Setting: Centers participating in the National Cancer Institute of Canada Clinical Trials Group. Patients: 111 eligible and evaluable patients hospitalized for severe neutropenia (neutrophil count less than 0.5 × 109/L lasting at least 14 days) who were receiving cytotoxic therapy for acute leukemia or bone marrow autografting. Intervention: One of three oral antibacterial prophylactic regimens (norfloxacin, 400 mg every 12 hours; ofloxacin, 400 mg every 12 hours; or ofloxacin, 400 mg, plus rifampin, 300 mg every 12 hours) beginning with cytotoxic therapy. Measurements: Incidence and cause of suspected or proven infection. Results: Microbiologically documented overall infection rates for norfloxacin, ofloxacin, and ofloxacin plus rifampin were 47%, 24%, and 9%, respectively (P < 0.001). Corresponding rates were 24%, 13%, and 3%, respectively for staphylococcal bacteremia (P = 0.03) and, 21%, 3%, and 3%, respectively for streptococcal bacteremia (P < 0.01). The pattern of bacteremia suggested that rifampin played a role in suppressing staphylococcal infection. Both ofloxacin alone and ofloxacin plus rifampin had a clinically significant antistreptococcal effect. Aerobic gram-negative rods were cleared from rectal surveillance cultures in all patients after a median of 5.5 days and caused infection in only one patient (0.9%). The reductions in the number of microbiologically documented infections among ofloxacin recipients and ofloxacin plus rifampin recipients were offset by concomitant increases in the number of unexplained fevers (24% of norfloxacin recipients, 53% of ofloxacin recipients, and 49% of ofloxacin plus rifampin recipients; P = 0.02). No statistically significant difference was found among the treatment arms with respect to the overall incidence of febrile neutropenic episodes as defined for this trial (79% for the norfloxacin group, 82% for the ofloxacin group, and 77% for the ofloxacin plus rifampin group). Conclusions: Quinolone-based antibacterial chemoprophylaxis protected patients from aerobic gram-negative bacillary infections. Augmentation of the gram-positive activity reduced the incidence of gram-positive infections but did not influence the overall incidence of febrile neutropenic episodes. *For additional investigators, see the Appendix.
Left Ventricular Performance and Coronary Flow after Coronary Embolization with Plastic Microspheres
Authors: R. G. Monroe, C. G. LaFarge, W. J. Gamble, A. E. Kumar, F. J. Manasek
Journal: Journal of Clinical Investigation (1971)

Coronary flow, left ventricular circumference, and left ventricular pressure were observed in the isovolumically contracting, isolated canine heart supported with arterial blood from a donor. Systolic pressure, heart rate, and coronary perfusion pressure were held constant while the coronary bed was progressively embolized with either large (average 865 mu) or small (average 10 mu) polystyrene microspheres. During embolization with large microspheres, coronary flow diminished progressively. After sufficient embolization, decreased ventricular performance was indicated by a rise in end-diastolic pressure. During embolization with small microspheres, coronary flow initially increased, which suggests the effective release of a vasodilator substance. Return of coronary flow to control levels occurred only after the end-diastolic pressure rose, on the average, to above 30 mm Hg. After embolization with both sizes of microspheres, ventricular diastolic pressure-volume relationships showed decreased ventricular compliance. This was attributed, in part, to edema of the ventricular wall and, in part, to focal shortening of the sarcomeres where the circulation was compromised. Embolization with both sizes of microspheres ultimately caused a decrease in ventricular performance, although when the systolic pressure was increased the usual relationship between peak developed wall stress, and end-diastolic pressure showed less of a descending limb than that found in the nonembolized, isolated heart. It is felt that the data summarized above have bearing on ventricular performance and coronary flow in clinical situations where hearts are perfused through pump oxygenator systems and are thereby subject to embolization from aggregated clumps of platelets and fibrin.
IL-2-mediated T cell proliferation in humans is blocked by a monoclonal antibody directed against monomorphic determinants of HLA-DR antigens.
Authors: A Moretta, R S Accolla, J C Cerottini
Journal: The Journal of Experimental Medicine (1982)

We have studied the effect on the interleukin (IL-) 2-dependent human T cell growth of two distinct monoclonal antibodies (Mab), D1-12 and 4F2, with specificity for common determinant of human Ia antigens and for a differentiation antigen expressed on all activated T cells, respectively. Strong inhibition of cell growth was found in cultures supplemented with the anti-Ia D1-12 Mab but not in cultures supplemented with 4F2 Mab. These results were obtained when either total mixed leukocyte culture (MLC) T cells or an MLC-derived T cell clone were used as indicator cell systems for IL-2 activity. The inhibition of cell growth appears to be mediated by a direct interaction of D1-12 Mab with the cells and not by a direct inactivation of the growth factor, as addition of the antibody to murine MLC T cells, which do not express the determinant defined by D1-12 Mab, resulted in no inhibition of their proliferation induced by the same source of human IL-2.
Abstract 3149: Targeting ERBB2-induced, lysosome-mediated invasion
Authors: Tuula Kallunki, Ditte M. Brix, Bo Rafn, Knut Kristoffer Bundgaard Clemmensen, Sofie Hagel Andersen, Noona Ambartsumian, Marja Jäättelä
Journal: Cancer Research (2014)

Abstract ErbB2 overexpression is strongly associated with invasive cancer with high recurrence and poor prognosis. Similarly, increased expression of lysosomal proteases, cysteine cathepsins, is observed in several cancers and correlates with enhanced angiogenesis, invasion and metastasis. We recently showed that ErbB2 level correlates positively with cysteine cathepsin B and L levels in primary breast cancer and that ErbB2 regulates the expression of cathepsins B and L leading to their increased activity in several ErbB2-positive breast cancer cell lines. The increased cysteine cathepsin activity is essential for the invasion of ErbB2 overexpressing breast cancer cells in 3-dimensional (3D) Matrigel cultures and is mediated by novel signaling network that involves TGFβR, ERK2-MAPK, PAK4, PKCα and CDC42bpβ kinases and two transcription factors, MZF1 and ETS1. With a pharmacological protein kinase inhibitor screen, using the ErbB2 inhibitor Lapatinib as positive control, we have now identified three inhibitors putatively targeting this novel ErbB2-induced signaling network. Our data shows that the treatment of ErbB2-positive, highly invasive breast or ovarian cancer cells with any of these inhibitors specifically reduces cysteine cathepsin expression, activity and invasion of these cancer cells in 3D Matrigel cultures. It also reverses lysosomal distribution from the invasion supporting pericellular position to less-invasive perinuclear position, where the lysosomal exocytosis and secretion of lysosome contents to extracellular space to assist extracellular matrix proteolysis becomes less likely. In this study we have identified novel inhibitors for ErbB2-induced invasion and discovered a novel, function for clinically used ErbB2 inhibitor Lapatinib in the regulation of lysosomal function and trafficking. Citation Format: Tuula Kallunki, Ditte M. Brix, Bo Rafn, Knut Kristoffer Bundgaard Clemmensen, Sofie Hagel Andersen, Noona Ambartsumian, Marja Jäättelä. Targeting ERBB2-induced, lysosome-mediated invasion. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3149. doi:10.1158/1538-7445.AM2014-3149
What Ecologic Analyses Cannot Tell Us About Medical Marijuana Legalization and Opioid Pain Medication Mortality
Authors: John W. Finney, Keith Humphreys, Alex H. S. Harris
Journal: JAMA Internal Medicine (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy
Authors: Myung Jin Oh, Heon Ju Lee, Si Hyung Lee
Journal: Clinical and Molecular Hepatology (2013)

Background/Aims Hepatic arterial infusion chemotherapy (HAIC) with 5-fluorouracil and cisplatin for intractable advanced hepatocellular carcinoma (HCC) may have survival benefits. We aimed to determine the efficacy and safety of HAIC for advanced HCC as first-line therapy. Methods A total of 54 patients who received only HAIC with 5-fluorouracil (750 mg/m2 on days 1-4) and cisplatin (25 mg/m2 on days 1-4) for advanced HCC from Jan. 2009 to Dec. 2011 were selected. According to Child-Pugh class, the overall survival (OS), progression-free survival (PFS), and adverse events after HAIC were investigated retrospectively. Results Median OS and PFS between the Child-Pugh A group (n=24) and the Child-Pugh B/C group (n=30) were 8.7 (95% confidence interval [CI]: 4.7-12.7) vs. 3.7 months (95% CI: 2.0-5.3), and 7.1 (95% CI: 3.8-10.4) vs. 3.6 months (95% CI: 2.0-5.2), respectively. Although median OS and PFS were not statistically significant between the two groups (P=0.079, P=0.196), the Child-Pugh class B/C tended to influence poor OS. Serious adverse events â¥ grade 3 occurred frequently in both groups (83.3 vs. 96.7%, P=0.159). Responders (22.2%, complete or partial response) significantly differed in median OS, compared to non-responders (13.1 vs. 4.4 months, P=0.019). Achievement of complete or partial response was an independent prognostic factor of OS (hazard ratio: 0.4, 95% CI: 0.2-0.8, P=0.011). Conclusions Achievement of response after HAIC provide a survival benefit in patients with advanced HCC, but HAIC should be administered cautiously in patients with Child-Pugh class B/C, because of a relatively low survival and high incidence of serious adverse events. Keywords: Carcinoma, Hepatocellular; Hepatic arterial infusion chemotherapy; Child-Pugh class; Overall survival; Progression-free survival
Tumorigenesis induced by the HHV8-encoded chemokine receptor requires ligand modulation of high constitutive activity
Authors: Peter J. Holst, Mette M. Rosenkilde, Denise Manfra, Shu-Cheng Chen, Maria T. Wiekowski, Birgitte Holst, Felix Cifire, Martin Lipp, Thue W. Schwartz, Sergio A. Lira
Journal: Journal of Clinical Investigation (2001)

ORF74 (or KSHV-vGPCR) is a highly constitutively active G protein–coupled receptor encoded by HHV8 that is regulated both positively and negatively by endogenous chemokines. When expressed in transgenic mice, this chemokine receptor induces an angioproliferative disease closely resembling Kaposi sarcoma (KS). Here we demonstrate that several lines of mice carrying mutated receptors deficient in either constitutive activity or chemokine regulation fail to develop KS-like disease. In addition, animals expressing a receptor that preserves chemokine binding and constitutive activity but that does not respond to agonist stimulation have a much lower incidence of angiogenic lesions and tumors. These results indicate that induction of the KS-like disease in transgenic mice by ORF74 requires not only high constitutive signaling activity but also modulation of this activity by endogenous chemokines.
Cost-effectiveness studies.
Authors: P Ward
Journal: BMJ (1978)

suggest that this discrepancy may be due to our Japanese patients having "concomitant medical problems" or "taking various medications"leading surprisingly to a normal CO2 response.To explain their own observations Dr Griffith and his colleagues suggest a functional disorder of the brain vessels in their hypertensive patients.Inhalation of CO2 in acute experimental hypertension causes an extreme rise in cerebral blood flow (CBF).'The finding of a normal rise in CBF in a hypertensive patient during CO, inhalation signifies structural and func- tional adaptation of the resistance vessels to the hypertensive state.This is analogous to the adaptation of CBF autoregulation to high blood pressure demonstrated in hypertensive patients.;The finding of a decreased response or even a decrease in CBF during CO2 inhalation, on the other hand, may be caused by stenosing atherosclerosis of the major brain vessels.Thus experimental carotid occlusion in the baboon diminishes the rise in CBF caused by CO2 inhalation by exhausting the arteriolar dilatatory capacity in the resting state.4Our Japanese patients had bilateral carotid angiography as part of their clinical investiga- tion and were included in the CO2 reactivity study only if no significant cerebral athero- sclerosis or other abnormality was present.Further, they were as a group somewhat younger than the patients of Dr Griffith and his colleagues (mean age 43 v 50 years), who were not investigated for atherosclerosis.It may also be mentioned that the extracerebral compartment of CBF, as measured by the 13'Xe-inhalation method used by them, would be expected to decrease during CO2 inhalation.Hypercapnia causes a generalised vasocon- striction (and thereby a rise in blood pressure) and has a dilatatory effect only in limited areas such as the cerebral and coronary circulations.In conclusion, the discrepancy between the results of Dr Griffith and his colleagues and our own may be due to more pronounced atherosclerosis in the British hypertensive patients or it may be due to differences in methodology.
Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase
Authors: Chee‐Kin Hui, Nancy Leung, Siu‐Tsan Yuen, Hai‐Ying Zhang, Kar‐Wai Leung, Lei Lu, Stephen K. F. Cheung, Wai‐Man Wong, George K. Lau
Journal: Hepatology (2007)

In view of the findings that high hepatitis B virus (HBV) deoxyribonucleic acid (DNA) is associated with increased risk of chronic hepatitis B (CHB)–related complications, disease progression in CHB patients in the immune-tolerant phase is uncertain. We evaluated disease progression in 57 immune-tolerant CHB patients with high HBV DNA. Each subject underwent an initial liver biopsy. In those who remained in the immune-tolerant phase, a follow-up liver biopsy was performed after 5 years of follow-up. Patients who developed elevated serum alanine aminotransferase (ALT) levels were discontinued from the study after a follow-up liver biopsy. Disease progression was defined as a 1-point increase in fibrosis stage. Initial liver biopsies showed the median fibrosis stage of the study patients was 1 (range 0–1). By the end of follow-up, 9 of the 57 patients (15.8%) had developed elevated serum ALT. In those who remained in the immune-tolerant phase, follow-up fibrosis stage was comparable with the initial fibrosis stage (P = 0.58). However, disease progression was greater in patients who developed elevated serum ALT when compared with those who remained in the immune-tolerant phase (5 of 9 vs. 3 of 48, respectively, P = 0.001). The median rate of fibrosis progression of patients who remained in the immune-tolerant phase was lower than that of patients with high serum ALT (0 U/year [range −0.40–0.20 U/year] versus 0.21 U/year [range 0–1.11 U/year], respectively, P = 0.04). Conclusion: CHB patients in the immune-tolerant phase have mild disease. In those who remained in the immune-tolerant phase in the present study, disease progression was minimal. However, immune-tolerant patients who progressed to the immune clearance phase often faced disease progression. (HEPATOLOGY 2007.)
Spleen Involvement at the Onset of Hodgkin's Disease
Authors: A. C. AISENBERG
Journal: Annals of Internal Medicine (1971)

Twenty-five patients with Hodgkin's disease were subjected to laparotomy and splenectomy because the usual clinical evaluation raised doubt as to the stage of the disease. Patients below the age of 50 with fever, sweats or chills, or a palpable spleen, a positive lymphangiogram, or two minor indications (equivocal lymphangiogram, splenomegaly by X ray, palpable liver, elevated sulfobromophthalein or alkaline phosphatase levels, or unfavorable histology) were explored. At laparotomy 13 patients had lymphoma of the spleen, but no patients had extrasplenic abdominal lymphoma without spleen involvement. Nine patients had positive para-aortic nodes; nine had positive celiac nodes, and four had a positive liver biopsy. In 7 individuals laparotomy resulted in reclassification into a more advanced stage; in 5 the clinical stage was reduced, and in 13 the stage was unchanged. These data are consistent with the view that the spleen is among the initial abdominal organs to which Hodgkin's disease spreads and that subsequently the abdominal nodes are involved.
Life Expectancies: Population or Person?
Authors: Alan L. Silver
Journal: Annals of Internal Medicine (1989)

Letters and Corrections1 August 1989Life Expectancies: Population or Person?Alan L. Silver, MD, MPH, David N. Rose, MDAlan L. Silver, MD, MPH, David N. Rose, MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-111-3-257 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editor: We applaud Sox and colleagues' analysis (1) of the role of exercise testing in coronary artery disease. We are concerned, however, with the interpretation of the results, specifically, how one assesses the average change in the life expectancy for an entire cohort as opposed to a change for a single individual.The authors state, for example, that for 60-year-old men with at least one risk factor, the average increase in life expectancy for the cohort is 17 days. However, given that the prevalence of disease is presumed to be 0.15, the average change in life expectancy for...References1. SoxLittenbergGarber HBA. The role of exercise testing in screening for coronary artery disease. Ann Intern Med. 1989;110:456-69. LinkGoogle Scholar2. RoseSchechterSilver DCA. Discounting, isoniazid, and tuberculosis [Letter]. JAMA. 1987;258:910. CrossrefMedlineGoogle Scholar3. SoxBlattHigginsMarion HMMK. Medical Decision Making. Boston: Butterworths; 1988. Google Scholar4. LaupacisSackettRoberts ADR. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318:1728-33. CrossrefMedlineGoogle Scholar1. SoxLittenbergGarber HBA. The role of exercise testing in screening for coronary artery disease. Ann Intern Med. 1989; 110:456-69. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Mt. Sinai Medical Center New York, NY 10029 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 August 1989Volume 111, Issue 3Page: 257-258KeywordsExerciseLife expectancyMedical risk factorsStable coronary artery disease Issue Published: 1 August 1989 PDF downloadLoading ...